November 5, 2025
1 min read

Supernus pauses new patient starts for Parkinson’s pump Onapgo, citing high demand

Some eight months into the launch of Onapgo, the Parkinson’s disease infusion pump Supernus Pharmaceuticals spent years fighting to get across the FDA finish line, the drugmaker is discovering that patients’ appetite for the wearable is more than it can currently handle.

Leave a Reply

Your email address will not be published.

Previous Story

Healthy Habits Slash Genetic Dementia Risk in Adults with Type 2 Diabetes

Next Story

CGIAR and HarvestPlus support national policy change to embed nutrition in every seed

Previous Story

Healthy Habits Slash Genetic Dementia Risk in Adults with Type 2 Diabetes

Next Story

CGIAR and HarvestPlus support national policy change to embed nutrition in every seed

Latest from Blog

ROFI Drives New Approach to Crop Nutrition

With input costs continuing to pressure farm budgets, some growers are making difficult decisions to reduce fertilizer application rates. While that strategy may ease upfront expenses, it is also accelerating a broader
Go toTop